Synthesis and biological evaluation of novel 1,3,4-thiadiazole derivatives as possible anticancer agents

Creative Commons License

ACAR ÇEVİK U., OSMANİYE D., LEVENT S., SAĞLIK B. N., KAYA ÇAVUŞOĞLU B., Karaduma A. B., ...More

ACTA PHARMACEUTICA, vol.70, no.4, pp.499-513, 2020 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 70 Issue: 4
  • Publication Date: 2020
  • Doi Number: 10.2478/acph-2020-0034
  • Journal Name: ACTA PHARMACEUTICA
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Agricultural & Environmental Science Database, BIOSIS, CAB Abstracts, EMBASE, International Pharmaceutical Abstracts, MEDLINE, Veterinary Science Database, Directory of Open Access Journals
  • Page Numbers: pp.499-513
  • Keywords: 1,3,4-thiadiazole, anticancer activity, aromatase inhibitory activity, MTT assay, INHIBITORY-ACTIVITY, AMINOGLUTETHIMIDE, HETEROCYCLES, BINDING
  • Anadolu University Affiliated: Yes

Abstract

The synthesis of new N-(5-substituted-1,3,4-thiadiazol-2-yl)-2-[5-(substituted amino)-1,3,4-thiadiazol-2-yl)thiolacetamide derivatives and investigation of their anticancer activities were the aims of this work. All the new compounds' structures were elucidated by elemental analyses, IR, H-1 NMR, C-13 NMR and MS spectral data. Anticancer activity studies of the compounds were evaluated against MCF-7 and A549 tumor cell lines. In addition, with the purpose of determining the selectivity of cytotoxic activities, the most active compound was screened against a noncancer NIH3T3 cell line (mouse embryonic fibroblast cells). Among the tested compounds, compound 4y (N-(5-ethyl-1,3,4-thiadiazol-2-yl)-2-((5-(p-tolylamino)-1,3,4-thiadiazol-2-yl)thio)acetamide), showed promising cytotoxic activity against MCF7 cancer cell with an IC50 value of 0.084 +/- 0.020 mmol L-1, and against A549 cancer cell with IC50 value of 0.034 +/- 0.008 mmol L compared with cisplatin. The aromatase inhibitory activity was evaluated for compound 4y on MCF-7 cell line showing promising activity with IC50 of 0.062 +/- 0.004 mmol L-1.